Generic name: eslicarbazepine acetate. Approved by the European Commission in April 2009 as an adjunctive therapy for adult patients with partial-onset seizures (including patients with secondary generalization). It is a novel, once-daily antiepileptic drug developed by Bial-Portela & Ca, S.A.
and is believed to exert its antiepileptic effect by regulating activity of sodium channels. Eisai Europe Ltd. possesses the marketing rights to the product in Europe.